Detalles de la búsqueda
1.
Pharmacokinetics and ADME Characterization of Intravenous and Oral [14C]-Linerixibat in Healthy Male Volunteers.
Drug Metab Dispos
; 49(12): 1109-1117, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34625435
2.
Regional gastrointestinal delivery of remogliflozin etabonate in humans.
Biopharm Drug Dispos
; 34(2): 79-86, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23111980
3.
Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies.
Drug Metab Dispos
; 40(11): 2090-101, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22851617
4.
Creatine ( methyl-d3) dilution in urine for estimation of total body skeletal muscle mass: accuracy and variability vs. MRI and DXA.
J Appl Physiol (1985)
; 124(1): 1-9, 2018 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28860169
5.
Total body skeletal muscle mass: estimation by creatine (methyl-d3) dilution in humans.
J Appl Physiol (1985)
; 116(12): 1605-13, 2014 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24764133
6.
Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus.
J Clin Pharmacol
; 50(6): 623-35, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20056803
7.
Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study.
J Clin Pharmacol
; 50(6): 636-46, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20200268
Resultados
1 -
7
de 7
1
Próxima >
>>